logo
logo

Clinchoice Raises $150M In Series E Round Led By China's Legend Capital

Jun 07, 2022•over 3 years ago

Amount Raised

$150 Million

Round Type

series e

Philadelphia

Description

ClinChoice, a Sino-US contract research organisation (CRO), has raised $150 million in as Series E funding round led by Legend Capital, the fund management arm of Chinese conglomerate Legend Holdings, according to a report by DealStreetAsia.

Company Information

Company

Clin Choice

Location

Philadelphia, Pennsylvania, United States

About

ClinChoice is a global clinical CRO, providing high-quality Integrated One-stop Service Offerings for new bio-pharmaceutical and medical device clients worldwide. Our Service Offerings cover Clinical Operation, Project Management, Biostatistics, Data Management, Biostatistical Programming, Regulatory Affairs, Medical Affairs, Feasibility Research, HGRAC Submission, Clinical Safety Management, Site Management Organization, Nature Medicine/Traditional Chinese Medicine and Phase I Clinical Research, etc. Now, ClinChoice has over 3,000 employees worldwide covering most of drug development hotbeds in US, China, multiple countries in Europe and Southeast Asia. Since its inception, ClinChoice has completed multiple rounds of financing, with investments from renowned institutional investors including Goldman Sachs, Lilly Asia Ventures, and DFJ Dragon Fund.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech